These are a group of rare diseases where blood clots form in tiny blood vessels throughout the body. This can damage organs and lead to serious complications. Examples include conditions like HUS and TTP.
Every report comes from a Lived member, sent anonymously.
Have you had Plasma Exchange for Thrombotic Microangiopathies?
Thrombotic microangiopathy (TMA) is a group of serious, uncommon disorders in which tiny blood clots form inside the body's smallest blood vessels. Those clots do damage in three ways at once. They use up platelets, the blood cells that normally plug small leaks, so people can bruise or bleed easily. They shred red blood cells squeezing past them, which causes anemia (a shortage of red blood cells). And they block blood flow to organs, most often the kidneys and the brain. TMA is an umbrella term rather than a single disease. The two best-known types are thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). HUS is further divided into typical HUS, which follows an E. coli gut infection and mostly affects young children, and atypical HUS (aHUS), a rarer form driven by an overactive part of the immune system. TMA can also develop as a complication of another illness, a medicine or a transplant. Telling these types apart matters, because the right treatment for one can be ineffective for another.
Each type of TMA has a different underlying cause. In TTP, the problem is a shortage of an enzyme called ADAMTS13, which normally trims a clotting protein so that it does not become too sticky. Most adults with TTP have the acquired form, in which the immune system makes antibodies that disable ADAMTS13. A rare inherited form, usually appearing in newborns or children, occurs when a child receives a faulty ADAMTS13 gene from each parent. Acquired TTP is more common in women and in Black Americans, and pregnancy, lupus, HIV and certain medicines, such as some chemotherapy drugs and quinine, can raise the risk. Typical HUS starts with an infection by a toxin-producing strain of E. coli (most often O157:H7), usually from undercooked ground beef, unpasteurized milk or juice, contaminated produce or contaminated water. The toxin enters the bloodstream and damages small vessels, especially in the kidneys. Children under 5 are most at risk. Atypical HUS often involves inherited changes in genes that control complement, a group of immune proteins that help fight infection but must be kept in check so they do not attack the body's own blood vessels. Less often, the body makes antibodies that block one of the proteins that keep complement in check. Having such a gene change does not by itself cause illness. An episode is typically set off by a trigger such as an infection or pregnancy. Other TMAs follow cancer, organ or stem cell transplants, autoimmune disease, some medicines or severely high blood pressure.
TMA is suspected when blood tests show the combination of a low platelet count and red blood cells being destroyed. A blood smear, in which blood is examined under a microscope, can show the torn fragments of red blood cells that small clots leave behind. Other tests support the picture: a raised lactate dehydrogenase (LDH) and bilirubin reflect red cells breaking down, and blood creatinine and urine tests show how well the kidneys are working. The next step is working out which type is present. A blood test of ADAMTS13 activity is central. Activity below 10% of normal, in someone with these findings, points strongly to TTP, and testing for antibodies against ADAMTS13 helps separate the acquired form from the inherited one, which is confirmed with genetic testing. Because ADAMTS13 results can take time, doctors often start treatment for suspected TTP before the results come back. In a child with recent bloody diarrhea, a stool test for toxin-producing E. coli supports typical HUS. Atypical HUS is largely a diagnosis made once TTP, E. coli infection and other causes have been ruled out, and genetic testing of complement genes may follow. Occasionally a kidney biopsy, a small sample of kidney tissue, is used to confirm damage in the kidney.
TMA is a medical emergency, and treatment usually begins in the hospital, often in intensive care. What that treatment is depends on the type. Acquired TTP is life-threatening without prompt treatment. The main treatment is plasma exchange, in which a machine removes the liquid part of the blood, along with the harmful antibodies, and replaces it with donor plasma that contains working ADAMTS13. It is repeated daily until platelet counts recover and organ problems settle. Medicines that calm the immune system, such as corticosteroids (for example, prednisone) and rituximab, reduce the antibodies. Caplacizumab (Cablivi), an injected antibody fragment that stops platelets from clumping on the sticky clotting protein, is added for adults and children 12 and older. Studies, including a randomized trial, show it brings platelet counts back faster and lowers the chance of an early relapse; a higher risk of bleeding is its main trade-off. Inherited TTP is treated by replacing the missing enzyme, either with plasma infusions or with a lab-made version of ADAMTS13 (Adzynma), which international guidelines now prefer for preventing episodes. Typical HUS after E. coli is treated with supportive care: careful fluids and minerals, blood transfusions when needed, blood pressure control and, if the kidneys stop working, temporary dialysis to filter the blood. Antibiotics are usually not used for the infection itself. Atypical HUS is treated with complement inhibitors, eculizumab (Soliris) or ravulizumab (Ultomiris), given by IV infusion. They block the overactive immune pathway and can stop blood cell destruction and reverse kidney injury, but they are not used for typical E. coli HUS. Because they sharply raise the risk of meningococcal infection, a dangerous form of meningitis and blood infection, people need meningococcal vaccines, usually at least 2 weeks before starting. Secondary TMA is managed by treating or removing its trigger, such as stopping a responsible medicine or controlling blood pressure.
The outlook depends heavily on the type. Most children with typical HUS recover without long-term problems, and those who need dialysis usually need it only briefly. A minority are left with kidney damage or high blood pressure, so kidney checks continue for some time after recovery. Many people recover from an episode of TTP, but relapses are common, sometimes years later. Follow-up usually includes regular blood counts and ADAMTS13 testing during remission, because a low ADAMTS13 level without symptoms can signal a higher chance of relapse, and doctors may then suggest preventive treatment such as rituximab. People with inherited TTP may need regular enzyme or plasma treatment for life. Atypical HUS can come back in repeated episodes, and kidney damage can build up with each one, sometimes leading to dialysis or a kidney transplant. Complement inhibitor treatment has greatly improved this outlook but involves regular infusions, vaccination and attention to infection. Whether and when treatment can safely be stopped is still being studied. For people considering a kidney transplant, genetic testing and preventive treatment matter because aHUS can recur in a new kidney. For any type, recovery from a hospital stay, intensive treatment and the uncertainty of a rare diagnosis can take time, and a specialist team in hematology or nephrology (kidney care) usually guides long-term care.
Talk with your care team about a plan for blood tests and follow-up if you have had TTP or aHUS, are planning a pregnancy, or are starting a new medicine, since pregnancy and some drugs can trigger an episode. If you have had TTP or aHUS, contact your hematology team the same day for a blood count if you notice new unexplained bruising, tiny red spots on the skin or unusual bleeding, even if you otherwise feel well. These can be early signs of a relapse, and a blood count can catch a falling platelet count before the brain or kidneys are affected. If a child has had diarrhea, especially bloody diarrhea, seek medical care right away if they pass much less urine than usual, look unusually pale, are extremely tired, or develop swelling, unexplained bruises or unusual bleeding. Go to an emergency department right away for unexplained bruising or tiny red spots on the skin together with confusion, a severe headache or extreme weakness, or for yellowing of the skin or eyes with extreme tiredness. Call 911 for a seizure, chest pain, sudden trouble speaking, sudden weakness or numbness on one side of the body, or drooping on one side of the face. If you take eculizumab or ravulizumab, get emergency care right away for a fever, a headache with a stiff neck or a new rash. These medicines raise the risk of meningococcal infection, which can become life-threatening very quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Thrombotic Microangiopathies is like, what's helped you, or ask the community a question.